Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

AstraZeneca AZ MedImmune Anand SubramonyAstraZeneca's MedImmune unit has appointed Dr Anand Subramony as its new vice president of drug delivery and device development.

He joins the company's biopharmaceutical development unit from Novartis, whose Institutes for Biomedical Research he previously worked for in Cambridge, Massachusetts.

While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group.

Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson & Johnson/Alza Corporation in Mountain View, California.

Dr Subramony will bring to MedImmune experience that includes drug-device combination products and a further boost to its focus on biologics delivery and device development.

13th March 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics